Parkinson’s Disease News

DUBLIN, Jan. 17, 2020 /PRNewswire/ -- The "Global Parkinson's Drug Market & Clinical Trial Insight 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report, Global Parkinson Drug Market & Clinical Trial Insight 2025, provides a thoughtful insight about the ... read more

Secondary parkinsonism can be caused by a cavernoma — a cluster of abnormal blood vessels — located in a brain region involved in voluntary movement control, a case report shows. The case-study, ”Nine-years follow-up of cavernoma located in basal ganglia mimicking Parkinson’s disease,” was published in the journal Clinical Neurology and Neurosurgery. Most patients (about 80–85%) diagnosed with Parkinson’s disease ... read more

A common gut bacteria called Bacilus subtilis (B. subtilis), which aids in digestion, shows the potential to counteract the misfolded alpha-synuclein protein central to Parkinson’s disease, according to a new study. B. subtilis, a so-called “good” bacteria, slowed the buildup of this protein in the nerve cells of worms engineered to produce human alpha-synuclein, and was found to clear some ... read more

A chemist from RUDN University has proposed a new method for the synthesis of secondary propargylamine used to create antidepressants, drugs for Parkinson's disease and other neurodegenerative ... read more

Are you a print subscriber? Activate your account. By George P. Slefo - 51 min 32 sec ago By David Fischer - 2 hours 18 min ago By Jeanine Poggi - 2 hours 37 min ago By Jessica Wohl - 3 hours 29 min ... read more

Steph Simmons spoke with one woman who is not letting Parkinson’s disease prevent her from conquering her goal. ... read more

Research by University at Buffalo biologists is providing new insights into alpha-synuclein, a small acidic protein associated with Parkinson's disease. ... read more

The International Parkinson Disease Genomics Consortium (IPDGC) has now been in existence for ten years. In an article published in the Journal of Parkinson's Disease the consortium reviews the progress made over the past decade in the genomics of Parkinson's disease (PD) and related disorders including Lewy body diseases, progressive supranuclear palsy, and multiple system atrophy and looks ahead at ... read more

Research by University at Buffalo biologists is providing new insights into alpha-synuclein, a small acidic protein associated with Parkinson's disease. Alpha-synuclein is known to form abnormal ... read more

Cerevel Therapeutics announced its launch of a series of Phase 3 clinical trials to evaluate its investigational therapy tavapadon, designed to improve motor function in people with Parkinson’s disease. The company will conduct three 27-week trials to evaluate tavapadon’s efficacy, safety, and tolerability in fixed doses — TEMPO-1 (NCT04201093) — and flexible doses — TEMPO-2 (NCT04223193) and TEMPO-3 (not yet ... read more

A potential oral therapy for Parkinson’s disease and amyotrophic lateral sclerosis (ALS) was seen to be safe and well-tolerated at various doses in a Phase 1 trial in healthy volunteers, its developer, Neuropore Therapies, announced. Steps are now underway to allow NPT520-34 to be evaluated in patients, the company said in a press release. NPT520-34 is a small molecule that, in different ... read more

After a minute it's time to move to the next station. Bender and about nine other seniors are part of the Rock Steady Boxing program, an exercise program for people with Parkinson's disease. "I feel ... read more

Research by University at Buffalo biologists is providing new insights into alpha-synuclein, a small acidic protein associated with Parkinson's disease. Alpha-synuclein is known to form abnormal ... read more

The International Parkinson Disease Genomics Consortium (IPDGC) has now been in existence for ten years. In an article published in the Journal of Parkinson's Disease the consortium reviews the ... read more

ADDIS- Investigators in West Baton Rouge Parish are investigating a murder involving a man with Parkinson's disease who was found suffocated inside his house on LA 1 Monday. The murder happened across ... read more

And he knows a thing or two about both. He's head of the Parkinson's rehabilitation unit at St. John of God Hospital in Venice, as well as an accomplished musician. According to the Irish Post, Volpe ... read more

WATCH ABOVE: People living with Parkinson's disease are seeing improvements in strength, balance and agility after taking part in Rock Steady Boxing classes. Retired nurse Barb Bender first ... read more

A team of researchers at Purdue University won a $4 million grant from the National Science Foundation to advance the development of a synthetic neuron platform to support future studies into brain health and neurodegenerative diseases like Parkinson’s. Diseases like Parkinson’s progressively damage and kill nerve cells, or neurons, in the brain. Although treatments may help ease disease-related symptoms, a ... read more

Biogen is adding Pfizer’s PF-05251749 — a regulator of the body’s inner clock — to its group of potential disease-modifying therapies for Parkinson’s and Alzheimer’s diseases. Biogen plans to test PF-05251749 in an upcoming Phase 1 clinical trial as a treatment to correct irregular sleep wake rhythm disorder in Parkinson’s and sundowning in Alzheimer’s. Non-motor symptoms associated with Parkinson’s disease include alterations ... read more

Researchers from the Universities of Edinburgh and Dundee found bacillus subtilis blocked the formation of alpha-synuclein that starve the brain of dopamine in people with the disease. ... read more

A common bacteria that boosts digestive health can slow—and even reverse—build-up of a protein associated with Parkinson's, new research suggests. ... read more

It turns out that specific strains of probiotics -- microorganisms that are found in the gut and aid digestion -- are able to help prevent, or even reverse, Parkinson's Disease. Newly released ... read more

My husband, Andy, has Parkinson's disease. A year ago, his neurologist recommended a new pill that he was to take at bedtime. We quickly learned that the medication would cost US$1,300 for a one-month supply of 30 pills. In addition, Andy could obtain the drug from only one specialty pharmacy and would have to use mail order. ... read more

Affiris is preparing for a Phase 2 clinical trial to test Affitope (PD01A), an experimental medicine that, if successful, could lead to a vaccine against  Parkinson’s disease. Affitope triggers the production of antibodies — molecules that recognize specific targets — against alpha-synuclein, a protein found in the brain that may be involved in transmitting information between neurons. While its precise function remains ... read more

Two Parkinson’s patients treated with AXO-Lenti-PD, an investigative gene therapy, in an ongoing clinical trial continue to show improvement 12 months later, Axovant, the therapy’s developer, said in a release. These findings at one year after treatment are important because this timepoint allows for a better assessment of therapy durability, and a more assured differentiation between placebo effects and therapeutic response, ... read more